Privacy PolicyTerms of Service
OslerMarket
K
Ask OslerLibraryLearn
OslerMarket

Filtered resources

Clinical library

444 resources

Explore a topic. Choose a collection. Find your next resource.

444 resources
Clear filters

Collections 3

Cardiology: ACS & Heart Failure16 resourcesHypertension9 resourcesECG & More17 resources

Collections

3 of 45
  • Cardiology: ACS & Heart Failure16 resourcesACS by Labu Albert · MANAGEMENT OF ACUTE CORONARY SYNDROME …
  • Hypertension9 resources2025 AHA/ACC Guideline for the Management of High Blood Pressure in Adults · ESC 2024 Hypertension Guidelines …
  • ECG & More17 resourcesAN INTRODUCTION TO THE ECG and arrythmias revision ECG Oct 2025 (2) · LITTLE BLACK BOOK OF ECG SECRETS …

Resources

24 shown
PRE-DISCHARGE AND EARLY POST-DISCHARGE MANAGEMENT OF PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: A SCIENTIFIC STATEMENT BY THE HEART FAILURE ASSOCIATION (HFA) OF THE ESC coverGuidelines & protocolsPRE-DISCHARGE AND EARLY POST-DISCHARGE MANAGEMENT OF PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: A SCIENTIFIC STATEMENT BY THE HEART FAILURE ASSOCIATION (HFA) OF THE ESCCardiology and Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy; Université Paris Cité, Inserm MASCOT, AP-HP·Cardiology· 2023· 43 pagesThis document provides a scientific statement on the management of patients hospitalized for acute heart failure, focusing on pre-discharge and early post-discharge strategies.
CARDIORENAL SYNDROME AND DIABETES: AN EVIL PAIRING coverClinical reviewsCARDIORENAL SYNDROME AND DIABETES: AN EVIL PAIRINGHospital Universitario Vall d'Hebron, Barcelona, Spain·Cardiology· 2023· 12 pagesThis document discusses the interplay between cardiorenal syndrome and diabetes, highlighting the implications for patient management and treatment strategies.
THE MEDICAL TREATMENT OF CARDIOGENIC SHOCK coverClinical reviewsTHE MEDICAL TREATMENT OF CARDIOGENIC SHOCKService de Médecine Intensive et Réanimation Brabois, CHRU Nancy, INSERM U1116, Université de Lorraine·Cardiology· 10 pagesThis review discusses the presentation and management of cardiogenic shock (CS), a leading cause of mortality worldwide, and explores recent advancements in its treatment.
ADVANCES IN THE MANAGEMENT OF CARDIOGENIC SHOCK coverClinical reviewsADVANCES IN THE MANAGEMENT OF CARDIOGENIC SHOCKDr. Rolf M·Cardiology· 12 pagesThis document reviews contemporary approaches to managing patients with cardiogenic shock (CS), integrating professional society recommendations and clinical study outcomes.
SPONTANEOUS CORONARY-ARTERY DISSECTION coverClinical reviewsSPONTANEOUS CORONARY-ARTERY DISSECTIONVanderbilt University Medical Center·Cardiology· 2020· 13 pagesThis review article discusses spontaneous coronary-artery dissection (SCAD) as a significant cause of myocardial infarction, particularly in young women, and highlights the differences in management compared to atherosclerotic myocardial infarction.
ADVANCES IN THE MANAGEMENT OF CARDIOGENIC SHOCK coverClinical reviewsADVANCES IN THE MANAGEMENT OF CARDIOGENIC SHOCKJacob C. Jentzer, MD·Cardiology· 12 pagesThis document reviews contemporary approaches to the management of cardiogenic shock (CS), focusing on clinical studies and professional society recommendations.
HEART FAILURE THERAPY: THE FIFTH CARD coverClinical reviewsHEART FAILURE THERAPY: THE FIFTH CARDCardiovascular Department, Pope John XXIII Hospital; Cardiology Unit, Milan Bicocca University·Cardiology· 2021· 4 pagesThis document discusses the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure, emphasizing a new approach to optimal drug therapy for patients with an ejection fraction <35%.
MANAGEMENT OF HEART FAILURE-RELATED CARDIOGENIC SHOCK coverClinical notesMANAGEMENT OF HEART FAILURE-RELATED CARDIOGENIC SHOCKAdvocate Heart Institute, Advocate Christ Medical Center; University of Illinois-Chicago; Cleveland Clinic; The University of Texas Health Science Center at Houston·Cardiology· 2022· 7 pagesThis document provides practical guidance for clinicians on the management of heart failure-related cardiogenic shock (HF-CS), emphasizing distinct presentations and the importance of early intervention.
HYponatraemia IN HEART FAILURE: TIME FOR NEW SOLUTIONS? coverClinical reviewsHYponatraemia IN HEART FAILURE: TIME FOR NEW SOLUTIONS?Medical University of Warsaw, Almazov National Medical Research Centre, National Medical Research Center for Therapy and Preventive Medicine, University of Glasgow·Cardiology· 7 pagesThis document reviews the prevalence and implications of hyponatraemia in heart failure, highlighting its association with increased mortality and morbidity. It discusses established and emerging therapies aimed at improving sodium homeostasis in heart failure patients.
USING THE NHS ENGLAND LIPID MANAGEMENT PATHWAY FUTURE PERSPECTIVES coverGuidelines & protocolsUSING THE NHS ENGLAND LIPID MANAGEMENT PATHWAY FUTURE PERSPECTIVESImperial College London·Cardiology· 2022· 7 pagesThis article provides a summary of the available lipid-lowering therapies in the UK and how they fit into national guidelines. It compares the current NICE lipid modification guidelines with international guidance from various cardiovascular societies.
ASSOCIATION OF BETA- BLOCKERS BEYOND 1 YEAR AFTER MYOCARDIAL INFARCTION AND CARDIOVASCULAR OUTCOMES coverClinical reviewsASSOCIATION OF BETA- BLOCKERS BEYOND 1 YEAR AFTER MYOCARDIAL INFARCTION AND CARDIOVASCULAR OUTCOMESUppsala University·Cardiology· 2023· 7 pagesThis study investigates the role of beta-blockers beyond the first year after myocardial infarction in patients without heart failure or left ventricular systolic dysfunction.
MANAGING HYPERTENSION AND CARDIOVASCULAR RISK IN RESOURCE-LIMITED SETTINGS coverClinical reviewsMANAGING HYPERTENSION AND CARDIOVASCULAR RISK IN RESOURCE-LIMITED SETTINGSInstitute·Cardiology· 14 pagesThis review discusses the management of hypertension as a critical factor in reducing cardiovascular risk, particularly in resource-limited settings. It highlights the low treatment and control rates of hypertension and suggests strategies for improvement.
BRUGADA SYNDROME coverClinical reviewsBRUGADA SYNDROMEDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University·Cardiology· 2023· 12 pagesBrugada syndrome (BrS) is a cardiac channelopathy associated with an elevated risk of arrhythmias and sudden cardiac death compared with the general population. This Primer discusses the evolving epidemiology, genetic understanding, diagnosis, and management of BrS.
HEART FAILURE AND LIVER DISEASE coverClinical reviewsHEART FAILURE AND LIVER DISEASEAndrew Xanthopoulos, MD, PhD; Randall C. Starling, MD, MPH; Takeshi Kitai, MD, PhD; Filippos Triposkiadis, MD, PhD·Cardiology· 2019· 11 pagesThis state-of-the-art review discusses the complex interactions between heart failure and liver disease, highlighting how systemic disorders affect both organs and the implications for patient management.
MANAGEMENT OF PATIENTS AT RISK OF ISCHEMIC STROKE WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN THE ABSENCE OF INTRACARDIAC THROMBUS: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION coverGuidelines & protocolsMANAGEMENT OF PATIENTS AT RISK OF ISCHEMIC STROKE WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN THE ABSENCE OF INTRACARDIAC THROMBUS: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATIONAmerican Heart Association·Cardiology· 18 pagesThis scientific statement summarizes the latest evidence regarding the risk of incident and recurrent stroke in patients with left ventricular (LV) dysfunction and provides best practice recommendations for their management after stroke.
ATRIAL SEPTAL DEFECT IN ADULTHOOD: A NEW PARADIGM FOR CONGENITAL HEART DISEASE coverClinical reviewsATRIAL SEPTAL DEFECT IN ADULTHOOD: A NEW PARADIGM FOR CONGENITAL HEART DISEASERoyal Brompton & Harefield Hospitals, National Heart and Lung Institute, Imperial College, and various other institutions·Cardiology· 2022· 14 pagesThis document provides a comprehensive review of atrial septal defects (ASDs) in adults, discussing various treatment options and their implications for patient care.
COMBINING LOOP WITH THIAZIDE DIURETICS FOR DECOMPENSATED HEART FAILURE: THE CLOROTIC TRIAL coverClinical reviewsCOMBINING LOOP WITH THIAZIDE DIURETICS FOR DECOMPENSATED HEART FAILURE: THE CLOROTIC TRIALHospital d’Olot i comarcal de la Garrotxa, Universitat de Vic—Universitat Central de Catalunya, Hospital Universitari Arnau de Villanova, Hospital Universitario de Getafe, Complejo Hospitalario de Soria, Hospital Clínico Universitario ‘Lozano Blesa’,·Cardiology· 2023· 11 pagesThis document presents findings from the CLOROTIC trial, which investigates the effects of combining loop diuretics with thiazide diuretics in patients with decompensated heart failure.
ARRHYTHMOGENIC MITRAL VALVE PROLAPSE AND SUDDEN CARDIAC DEATH: AN UPDATE AND CURRENT PERSPECTIVES coverClinical reviewsARRHYTHMOGENIC MITRAL VALVE PROLAPSE AND SUDDEN CARDIAC DEATH: AN UPDATE AND CURRENT PERSPECTIVESDivision of Cardiology, Department of Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy·Cardiology· 2023· 26 pagesThis document provides an update on the relationship between arrhythmogenic mitral valve prolapse (MVP) and sudden cardiac death, focusing on the mechanisms of electric instability and the risk factors involved.
GREAT DEBATE: CONDUCTION SYSTEM PACING WILL REPLACE CONVENTIONAL CARDIAC RESYNCHRONIZATION THERAPY coverClinical reviewsGREAT DEBATE: CONDUCTION SYSTEM PACING WILL REPLACE CONVENTIONAL CARDIAC RESYNCHRONIZATION THERAPYDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center; Department of Medicine, McGill University Health Center; First Department of Cardiology, Interventional Electrocardiology and·Cardiology· 2024· 11 pagesThis document presents a debate on whether conduction system pacing will replace conventional cardiac resynchronization therapy, featuring multiple expert opinions and evidence from recent studies.
INFECTIVE ENDOCARDITIS: DIAGNOSIS, ANTIBIOTIC THERAPY, AND MANAGEMENT: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION coverClinical reviewsINFECTIVE ENDOCARDITIS: DIAGNOSIS, ANTIBIOTIC THERAPY, AND MANAGEMENT: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATIONAmerican Heart Association·Cardiology· 2023· 27 pagesThis scientific statement provides updated information on the diagnosis, antibiotic therapy, and management of infective endocarditis, reflecting changes in its incidence and treatment options since the last statement in 2015.
HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION: A HEART FAILURE SOCIETY OF AMERICA SCIENTIFIC STATEMENT coverClinical reviewsHEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION: A HEART FAILURE SOCIETY OF AMERICA SCIENTIFIC STATEMENTHeart Failure Society of America·Cardiology· 16 pagesThis document provides a comprehensive review of the epidemiology, clinical characteristics, and pathophysiology of heart failure with mildly reduced ejection fraction (HFmrEF), along with a clinical framework for treatment.
GUIDELINE-DIRECTED MEDICAL THERAPY FOR HFrEF: SEQUENCING STRATEGIES AND BARRIERS FOR LIFE-SAVING DRUG THERAPY coverClinical reviewsGUIDELINE-DIRECTED MEDICAL THERAPY FOR HFrEF: SEQUENCING STRATEGIES AND BARRIERS FOR LIFE-SAVING DRUG THERAPYJishnu Malgie, Pascal R. D. Clephas, Hans-Peter Brunner-La Rocca, Rudolf A. de Boer, Jasper J. Brugts·Cardiology· 2023· 14 pagesThis document reviews the advancements in the treatment of heart failure with reduced ejection fraction (HFrEF) and discusses the challenges in implementing guideline-directed medical therapy (GDMT). It emphasizes the importance of rapid drug implementation and up-titration to improve patient outcomes.
NEW DRUG THERAPIES FOR HYPERTENSION coverClinical reviewsNEW DRUG THERAPIES FOR HYPERTENSIONINSERM CIC1418, Hôpital Européen Georges Pompidou, APHP, Université Paris Cité, University of Washington·Cardiology· 2026· 15 pagesThis document discusses emerging antihypertensive drug therapies that target physiological pathways beyond conventional drug classes, addressing the need for innovative approaches in hypertension care.
DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CKD G3–G5D coverClinical reviewsDIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CKD G3–G5DUmeå University, Uppsala University·Cardiology· 10 pagesThis study investigates the risk of ischemic stroke and major bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease treated with direct oral anticoagulants compared to warfarin.
PreviousPage 9 of 19Next

© 2026 Osler Market

Library·Ask Osler·Learn·Terms·Privacy·Support·WhatsApp Channel

For learning purposes. Always consult clinical guidelines.

Ask OslerLibraryLearn
HomeAskLibraryLearnAccount